Egetis Therapeutics Logo

Egetis Therapeutics

ISIN: SE0003815604 | Ticker: EGTX | LEI: 549300RZCKGWRUBPMY22
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Sweden

About Egetis Therapeutics

Company Description

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Company’s lead candidate Emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) Emcitate has shown highly significant and clinically relevant results on serum T3 levels and secondary clinical endpoints. As a result of fruitful regulatory interaction Egetis intends to submit a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) in the first half of 2023 based on existing clinical data.

Year founded

2006

Headquarters

Klara Norra Kyrkogata 26, 11122 Stockholm – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2021 01.01.2022 01.01.2023
Assets N/A 569,300,000.00 561,100,000.00
Noncurrent Assets N/A 416,400,000.00 413,700,000.00
Licences And Franchises N/A 6,500,000.00 5,400,000.00
Other Noncurrent Financial Assets N/A 800,000.00 800,000.00
Current Assets N/A 152,900,000.00 147,400,000.00
Inventories N/A 700,000.00 600,000.00
Current Trade Receivables N/A 3,500,000.00 3,800,000.00
Current Prepayments And Current Accrued Income Other Than Current Contract Assets N/A 1,400,000.00 8,900,000.00
Other Current Receivables N/A 3,300,000.00 6,400,000.00
Cash and cash equivalents 287,900,000.00 144,000,000.00 127,700,000.00
Equity And Liabilities N/A 569,300,000.00 561,100,000.00
Equity 630,700,000.00 527,000,000.00 506,200,000.00
Issued Capital N/A 8,700,000.00 11,300,000.00
Retained Earnings N/A -745,800,000.00 -939,600,000.00
Other Reserves N/A 1,300,000.00 6,100,000.00
Additional Paidin Capital N/A 1,262,800,000.00 1,428,400,000.00
Noncurrent Liabilities N/A 3,100,000.00 5,500,000.00
Noncurrent Payables On Social Security And Taxes Other Than Income Tax N/A 400,000.00 4,400,000.00
Other Noncurrent Liabilities N/A 2,700,000.00 1,100,000.00
Current Liabilities N/A 39,200,000.00 49,400,000.00
Trade And Other Current Payables To Trade Suppliers N/A 4,600,000.00 20,000,000.00
Other Current Liabilities N/A 17,200,000.00 5,700,000.00
Line item in (sek) 01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 38,200,000.00 22,600,000.00
Other Income 300,000.00 0.00
Employee Benefits Expense 30,100,000.00 52,000,000.00
Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 2,500,000.00 2,700,000.00
Other Expense By Nature 14,500,000.00 22,300,000.00
Profit Loss From Operating Activities -105,700,000.00 -198,100,000.00
Finance Income 1,300,000.00 5,000,000.00
Finance Costs 200,000.00 700,000.00
Profit Loss Before Tax -104,500,000.00 -193,800,000.00
Income Tax Expense Continuing Operations 0.00 0.00
Profit (loss) -104,500,000.00 -193,800,000.00
Line item in (sek) 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -104,500,000.00 -193,800,000.00
Adjustments For Reconcile Profit Loss N/A -28,300,000.00 10,900,000.00
Other Adjustments For Noncash Items N/A 2,700,000.00 9,400,000.00
Adjustments For Reconcile Profit Loss N/A -28,300,000.00 10,900,000.00
Interest Paid Classified As Operating Activities N/A 0.00 100,000.00
Interest Received Classified As Operating Activities N/A 100,000.00 900,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 0.00 0.00
Cash Flows From Used In Operating Activities N/A -130,100,000.00 -173,500,000.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 5,000,000.00 1,700,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 200,000.00 0.00
Cash Flows From Used In Investing Activities N/A -6,000,000.00 -1,700,000.00
Proceeds From Issuing Shares N/A 0.00 177,400,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 7,500,000.00 7,500,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 1,400,000.00 1,600,000.00
Cash Flows From Used In Financing Activities N/A -8,900,000.00 155,700,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A -145,000,000.00 -19,500,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 1,100,000.00 3,200,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A -145,000,000.00 -19,500,000.00
Cash and cash equivalents 287,900,000.00 144,000,000.00 127,700,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
07.07.23 Henrik Krook Other Buy SEK 133,704.12
06.07.23 Christian Sonesson Other Buy SEK 14,391.68
06.07.23 Christian Sonesson Other Buy SEK 7,920.00
05.07.23 Christian Sonesson Other Buy SEK 5,452.96
04.07.23 Nicklas Westerholm Other Buy SEK 60,632.50
05.06.23 Elisabeth Svanberg Other Buy SEK 54,586.80
01.06.23 Kristina Sjöblom Nygren Other Buy SEK 24,650.00
31.05.23 Mats Blom Other Buy SEK 991,600.00
20.06.22 Henrik Krook Other Buy SEK 281,176.69
20.06.22 Henrik Krook Other Sell SEK 274,291.77

Capital markets information

ISIN

SE0003815604

LEI

549300RZCKGWRUBPMY22

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.